Figure S2

| Cell Line | NC | MUC3A KD |
|-----------|----|----------|
| MUC3A     |    |          |
| GAPDH     |    |          |

- **H1975**: MUC3A KD shows reduced expression compared to NC.
- **PC9**: MUC3A KD shows reduced expression compared to NC.
- **1299**: MUC3A KD shows reduced expression compared to NC.

MUC3A: ~266 KDa
GAPDH: ~36 KDa
| REAGENT or RESOURCE | SOURCE | IDENTIFIER       |
|---------------------|--------|------------------|
| MUC3A               | abcam  | Cat#ab138510     |
| PD-L1               | BD biosciences | Cat#557924 |
| EGFR                | proteintech | Cat#66455-1-lg  |
| p-EGFR              | Cell Signaling Technology | Cat#2220S |
| AKT                 | Cell Signaling Technology | Cat#4691 |
| p-AKT               | Cell Signaling Technology | Cat#4060 |
| MEK                 | Cell Signaling Technology | Cat#11049 |
| p-MEK               | Cell Signaling Technology | Cat#9154 |
| ERK                 | proteintech | Cat#16443-1-AP  |
| p-ERK               | Cell Signaling Technology | Cat#4370 |
| GAPDH               | proteintech | Cat#10494-1-AP  |
| HRP-conjugated Affinipure Goat Anti-Rabbit IgG(H+L) | proteintech | Cat#SA00001-2 |
| HRP-conjugated Affinipure Goat Anti-Mouse IgG(H+L) | proteintech | Cat#SA00001-1 |
| MEK inhibitor       | MedChemExpress | Cat#HY-10999A |
| PI3K inhibitor      | MedChemExpress | Cat#HY-50094 |
| SC79                | MedChemExpress | Cat#HY-18749 |
| Honokiol            | MedChemExpress | Cat#HY-N0003 |
**Table S2** Correlation between PD-L1 levels in NSCLC patients and their clinicopathologic characteristics

| Clinical pathology          | PD-L1\(^{low}\) | PD-L1\(^{high}\) | N  | p value |
|-----------------------------|-----------------|------------------|----|---------|
| Gender                      |                 |                  |    |         |
| Male                        | 24              | 27               | 51 | p = 0.869 |
| Female                      | 20              | 21               | 41 |         |
| Age                         |                 |                  |    |         |
| ≤ 60                        | 20              | 18               | 38 | p = 0.439 |
| > 60                        | 24              | 30               | 54 |         |
| Tumor size (cm)             |                 |                  |    |         |
| < 4                         | 19              | 26               | 45 | p = 0.229 |
| ≥ 4                         | 19              | 15               | 34 |         |
| None                        | 6               | 7                | 13 |         |
| Histological grade          |                 |                  |    |         |
| I/I-II                      | 4               | 3                | 7  | p = 0.300 |
| II                          | 26              | 24               | 50 |         |
| II-III/III                  | 11              | 20               | 31 |         |
| I-III                       | 3               | 1                | 4  |         |
| Clinical Stage              |                 |                  |    |         |
| I                           | 12              | 13               | 25 | p = 0.942 |
| II                          | 11              | 10               | 21 |         |
| III-IV                      | 11              | 10               | 21 |         |
| Non                         | 10              | 15               | 25 |         |
| Lymph node status           |                 |                  |    |         |
| < 4                         | 11              | 14               | 25 | p = 0.519 |
| ≥ 4                         | 31              | 29               | 60 |         |
| Non                         | 2               | 5                | 7  |         |
| Carcinoma                   |                 |                  |    |         |
| Primary                     | 44              | 48               | 92 | p < 0.0001* |
| Adjacent                    | 88              | 0                | 88 |         |

*P* value represents the probability from a chi-square test for tissue PD-L1 levels between variable subgroups, *p* < 0.05.